Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    12682289 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  Study of Ipilimumab in the Immune System
Condition: Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma
Intervention: Drug: Ipilimumab at 10 mg/kg dose

Indicates status has not been verified in more than two years